Authors : K. H. Charde; K. M. Bhusari

Volume/Issue : Volume 11 - 2026, Issue 3 - March

Google Scholar : https://tinyurl.com/4nwpvaca

Scribd : https://tinyurl.com/394a2p9z

DOI : https://doi.org/10.38124/ijisrt/26mar1235

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by hormonal imbalances, chronic anovulation, hyperandrogenism, and metabolic disturbances. Recently, herbal therapies have gained attention as complementary approaches due to their multi-targeted mechanisms and favorable safety profiles. This review explores the combined therapeutic potential of Vitex agnus-castus and Asparagus racemosus in managing hormonal dysfunction associated with PCOS. Vitex agnus-castus primarily influences the hypothalamic–pituitary axis through dopaminergic activity, leading to reduced prolactin levels, improved LH/FSH ratio, enhanced luteal phase function, and restoration of ovulation. Meanwhile, Asparagus racemosus, rich in steroidal saponins and phytoestrogens, directly affects ovarian tissues by modulating estrogen receptors, promoting follicular development, reducing oxidative stress, and supporting progesterone balance. Together, these herbs offer complementary regulatory support, addressing both upstream pituitary signaling and downstream ovarian hormone production. Their combination shows promise in enhancing menstrual regularity, alleviating androgen-related symptoms, and promoting overall reproductive health in women with PCOS. further advanced clinical trials are essential to validate their synergistic efficacy, identify optimal dosages, and confirm long-term safety. This review underscores the importance of integrating multi-herbal strategies in managing hormonal dysregulation in PCOS.

References :

1. Dayani Siriwardene, S.A.; Karunathilaka, L.P.; Kodituwakku, N.D.; Karunarathne, Y.A. Clinical efficacy  of ayurveda treatment regimen on subfertility with poly cystic ovarian syndrome (P COS). Ayu, 2010,  31(1), 24-27. http://dx.doi.org/10.4103/0974-8520.68203 PMID: 22131680
2. Ndefo, U.A.; Eaton, A.; Green, M.R.; Robinson, M.G. Polycystic ovary syndrome: A review of treatment options with a focus on pharmacological approaches. P&T, 2013, 38(6), 336-355. PMID: 23946629
3. Gildner, T. E. (2021). Reproductive hormone measurement from minimally invasive sample types: Methodological considerations and anthropological importance. American Journal of Human Biology, 33(1), e23535.
4. MacKendrick, N. A., & Troxel, H. (2022). Like a finely-oiled machine: Self-help and the elusive goal of hormone balance. Social Science & Medicine, 309, 115242.
5. Zehravi, M., Maqbool, M., & Ara, I. (2022). Polycystic ovary syndrome and infertility: an update. International Journal of Adolescent Medicine and Health, 34(2), 1-9.
6. Latha, S.T.; Prasanna, J.L.; Rani, M.J.; Divya, K.; Babu, A.M.S. A review on natural remedies for prevailing polycystic ovarian dis order. Indo Am. J. Pharm., 2015, 5(10), 3307-3315.
7. Balaji, S.; Amadi, C.; Prasad, S.; Bala Kasav, J.; Upadhyay, V.; Singh, A.K.; Surapaneni, K.M.; Joshi, A. Urban rural comparisons of polycystic ovary syndrome burden among adolescent girls in a hospital setting in India. BioMed Res. Int., 2015, 2015(158951), 158951.
8. Pylypchuk, R., Wells, S., Kerr, A., Poppe, K., Harwood, M., Mehta, S., & Jackson, R. (2021). Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study. The Lancet, 397(10291), 2264-2274.
9. Zhu, T., Cui, J., & Goodarzi, M. O. (2021). Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke. Diabetes, 70(2), 627-637.
10. Hasan, N., Ahmad, N., Zohrameena, S., Khalid, M., & Akhtar, J. (2016, March 30). Asparagus racemosus: FOR MEDICINAL USES and PHARMACOLOGICAL ACTIONS. International Journal of Advanced Research. https://www.journalijar.com/article/.
11. Pachiappan, S.; Matheswaran, S.; Saravanan, P.P.; Gayathiri, M. Medicinal plants for polycystic ovary syndrome: A review of phy tomedicine research. Int. J. Herb, 2017, 5(2), 78 80. http://dx.doi.org/10.22192/ijcrcps
12. Kalia, V.; Jadav, A.N.; Bhuttani, K.K. In vivo effect of Asparagus racemosus on serum gonadotrophin levels in immature female wis tar rats. 2nd world congress of Biotech; Devision Of Herbal medicine: NBRI: Lucknow, 2003, p. 40.
13. Medicine: NBRI: Lucknow, 2003, p. 40. Gaitond , B.B.; Jetmalani, M.H. Antioxytocic action of saponin isolated from Asparagus racemosus Willd (Shatavari) on uterine muscle. Arch. Int. Pharmacodyn. Ther., 1969, 179(1), 121-129. PMID: 5348388.
14. Sharma, K.; Bhatnagar, M. Asparagus racemosus (Shatavari): A versatile female tonic. Int. . phar, 2011, 2(3), 855-863.
15. Pandey, A.K.; Gupta, A.; Tiwari, M.; Prasad, S.; Pandey, A.N.; Yadav, P.K.; Sharma, A.; Sahu, K.;  Asrafuzzaman, S.; Vengayil, D.T.; Shrivastav, T.G.; Chaube, S.K. Impact of stress on female re productive health disorders: Possible beneficial effects of shata vari (Asparagus racemosus). Biomed. Pharmacother., 2018, 103, 46-49 http://dx.doi.org/10.1016/j.biopha.2018.04.003 PMID: 29635127
16. Home Remedies. Shatavari (Asparagus racemosus) plant benefits and Pictures. Available from: https://www.homeremediess. com/medicinal-plants-shatavari-benefits/ [Accessed January 10, 2021]
17. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus)—phytotherapy of gynecologic disorders. Phytomedicine. 2003;10(4):348–357.
18. Milewicz A, Gejdel E, Sworen H, et al. Treatment of luteal phase defects with Vitex extract. Arzneimittelforschung. 1993;43(6):752–756.
19. Brown D. Vitex agnus-castus: Traditional uses in female reproductive disorders. J Am Nutr Assoc. 1994;2(3):5–9.
20. Sliutz G, Speiser P, Schultz A, et al. Prolactin-suppressive effects of chaste tree. Horm Metab Res. 1993;25(9):253–255.
21. Jarry H, Spengler B, Porzel A, et al. Dopaminergic compounds in Vitex agnus-castus. Planta Med. 1994;60(4):326–327.
22. Schellenberg R. Treatment of PMS with Vitex agnus-castus. BMJ.  2001;322(7279):134–137.
23. Lauritzen C. Vitex’s effect on corpus luteum function. Gynecol Endocrinol. 1997;11(Suppl 1):1–21.
24. Berger D, Schaffner W. Influence of Vitex on luteal phase hormones. Ther Umsch. 2002;59(3):181–185.
25. Loch EG, Selle H, Boblitz N. Vitex extract benefits in menstrual cycle disorders. Phytomedicine. 2000;7(5):373–381.
26. Liu J, Burdette JE, Sun Y, et al. Estrogenic activity of Vitex flavonoids. J Agric Food Chem. 2001;49(5):2472–2479.
27. Morales S, Becerra M, Lagos P. Antiandrogenic properties of Vitex constituents. J Ethnopharmacol. 2011;135(2):346–352.
28. Daniele C, Thompson Coon J, Pittler MH, et al. Vitex in hormonal disorders: A systematic review. J Womens Health. 2005;14(7):601–609.
29. Jarry H, Gorkow C, Wuttke W. Vitex’s effects on LH and FSH secretion. Exp Clin Endocrinol. 1993;101(2):129–138.
30. Van Die MD, Burger HG, Teede HJ, et al. Herbal therapy and neuroendocrine modulation in PCOS. Complement Ther Med. 2009;17(4):273–280.
31. Romualdi D, Costantini B, De Cicco S, et al. Vitex and improved GnRH pulsatility. Hum Reprod. 2008;23(6):1470–1476.